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Abstract
Epoxyeicotrienoic acids (EETs) are cytochrome P450-dependent anti-hypertensive and anti-inflammatory derivatives of
arachidonic acid, which are highly abundant in the kidney and considered reno-protective. EETs are degraded by the enzyme
soluble epoxide hydrolase (sEH) and sEH inhibitors are considered treatment for chronic renal failure (CRF). We determined
whether sEH inhibition attenuates the progression of CRF in the 5/6-nephrectomy model (5/6-Nx) in mice. 5/6-Nx mice were
treated with a placebo, an ACE-inhibitor (Ramipril, 40 mg/kg), the sEH-inhibitor cAUCB or the CYP-inhibitor fenbendazole for 8
weeks. 5/6-Nx induced hypertension, albuminuria, glomerulosclerosis and tubulo-interstitial damage and these effects were
attenuated by Ramipril. In contrast,cAUCB failed tolower the blood pressure and albuminuria was more severe as compared to
placebo. Plasma EET-levels were doubled in 5/6 Nx-mice as compared to sham mice receiving placebo. Renal sEH expression
wasattenuatedin5/6-NxmicebutcAUCBin theseanimalsstillfurther increasedtheEET-level.cAUCBalsoincreased5-HETEand
15-HETE, which derive from peroxidation or lipoxygenases. Similar to cAUCB, CYP450 inhibition increased HETEs and promoted
albuminuria. Thus, sEH-inhibition failed to elicit protective effects in the 5/6-Nx model and showed a tendency to aggravate the
disease. These effects might be consequence of a shift of arachidonic acid metabolism into the lipoxygenase pathway.
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Introduction
Epoxyeicosatrienoic acids (EETs) are anti-inflammatory deriv-
atives of arachidonic acid (AA) which are generated by
cytochrome P450 (CYP) epoxygenases [1]. EETs are antihyper-
tensive, anti-inflammatory, anti-proliferative and pro-fibrinolytic.
They act as an endothelium-derived hyperpolarizing factor
(EDHF) in some vascular beds [1]. The CYP450 expression in
the kidney is high and EETs promote renal sodium excretion
[1,2]. EET levels are dependent on the activity and expression of
the CYP epoxygenases, which generate them and the enzyme
soluble epoxide hydrolase (sEH) which converts the EETs to their
corresponding dihydroxyeicosatrienoic acids (DHETs) [3].
DHETs subsequently leave the cell, can be conjugated in the
liver and be excreted by liver or kidney [2,4]. The activity of the
sEH is therefore thought to be a major determinant of EET
bioavailability [4]. Genetic deletion of the sEH as well as
pharmacological inhibition increase plasma EET levels and
potentiate their effects [5], and thus sEH inhibition elicits anti-
hypertensive and anti-inflammatory effects [2,5,6]. Indeed, we
have previously shown that sEH inhibition reduces angiotensin II-
induced hypertension [7], neo-intima formation in hyperlipidemic
mice [8] and vascular remodelling in the monocrotaline-model in
rats [9].
Hypertension and inflammation are important progression
factors for renal disease and thus it is logical to assume that sEH
inhibition is a strategy to prevent progression of renal diseases
[2,5]. Indeed, it has been demonstrated that sEH inhibition
improves renal vascular function, decreased glomerular injury and
renal inflammation in rat models of angiotensin-induced and
DOCA-salt hypertension [10–12]. A main limitation of these
models is however that their high inflammatory activity does not
necessarily reflect the situation of chronic renal disease in man
which is dominated by sclerotic and fibrotic processes and which is
characterized by a progressive, self-perpetuating nature [13,14]. In
animal experiments such a situation can be modelled by 5/6-
nephrectomy (5/6-Nx). In this remnant kidney model, the
substantial reduction in renal mass leads to compensatory renal
hypertrophy, glomerula hyperfiltration and subsequently progres-
sive chronic renal failure as consequence of glomerulo-sclerosis
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e11979and interstitial fibrosis [15–17]. Although also in the remnant
kidney model, the renin-angiotensin-system is involved in disease
progression [18], it is only one of several factors contributing to a
complex disease scenario.
Given the similarities between the remnant kidney model in
rodents and the pathophysiology of progressive chronic renal failure
inhumans, we postulated that sEH inhibitors could beof therapeutic
value.Wetestedthishypothesisintherodentremnantkidneymodel.
Unexpectedly and in contrast to previous data from inflammation
driven renal failure models we observed that sEH inhibition had a
tendency to accelerate the disease process in this model.
Methods
Animal preparations
SV129 which were purchased from Charles Rivers Laboratories
(Sulzfeld, Germany) were used for this study, as other strains do
not develop progressive renal failure mice [19]. Animals were
housed in cages at constant temperature (22uC) and humidity
(50%) and were exposed to a 12-hour dark/light cycle. Food and
water were supplied ad libitum. The experiments were performed
in accordance with the National Institutes of Health Guidelines on
the Use of Laboratory Animals. Both, the University Animal Care
Committee and the Federal Authorities for Animal Research of
the Regierungspra ¨sidium Darmstadt (Hessen, Germany) approved
the study protocol (approval number V54-19c20/15-F28/05 and -
F61/16). After 7 days of adaptation, the animals were randomly
allocated to 5/6 nephrectomy (5/6-Nx) or sham operation. The
surgery was performed under Isoflurane anaesthesia as previous
described by others with modifications [19]. In brief: A left dorsal
longitudinal incision was performed to expose the left kidney. The
upper branch of the left renal artery was ligated by 6–0 prolene
suture to produce about one third area with visible renal ischemia
infarct; the lower pole of the left kidney (about one third kidney
size) was removed by cautery. After 7 days of recovery, the right
kidney was exposed in a similar preparation and removed after
decapsulation and ligation of the vessels and the ureter to induce a
total 5/6 nephrectomy (5/6-Nx). The control animals were sham
operated in parallel by decapsulating the kidney. Early mortality
within the first 3 days was approx. 20%. Subsequently, animals
were randomized to the different treatment groups (n=16 per
group). The substances were administered as follows: The sEH
inhibitor cis-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-ben-
zoic acid (cAUCB, final concentration 8 mg/l), the ACE-inhibitor
ramipril (final concentration 40 mg/l) were given with the
drinking water, fenbendazole with the chow (100 mg/kg).
Ramipril was kindly provided by Sanofi-Aventis, fenbendazole
was from the university of Mainz (Zentrale Versuchstiereinheite -
ZVTE) and cAUCB was synthesized by one of the coauthor as
previously reported [20].
Blood pressure measurements
Systolic blood pressure was assessed at 4 and 8 weeks after
initiation of treatment. By an automated tail-cuff Blood Pressure
Monitor (Visitech) in conscious, trained mice at room temperature
as reported previously [7]. In a subset of animals blood pressure
measurements were confirmed by telemetry with the aid of the
data science instruments (DSI) system with the catheter being
placed in the right iliac artery.
Analysis of kidney function
Mice were placed in metabolic cages (Tecniplast) for 24-hour
for urine collection. Urinary albumin was determined using the
albumin-to-creatinine ratio (ACR). Urinary albumin and creati-
nine levels were measured by ELISA (Bethyl Laboratories,
Montgomery, USA) and a creatinine assay kit (Labor+Technik,
Berlin, Germany), respectively.
Histological analysis
After the induction of terminal anesthesia, the abdominal vessels
were opened, the thoracic cavity was opened, a canula was
inserted into the right ventricle and the animals were perfused with
phosphate-buffered saline (PBS). After the perfusion, kidneys were
removed and fixed with 4% paraformaldehyde/PBS solution. The
samples were subsequently embedded in paraffin and 2-mm
sections were cut and stained with haematoxylin/eosin (HE),
perjodic acid Schiff (PAS) and Sirius red (fibrous tissue stain).
Thereafter, the stained kidney sections were analyzed by
morphometry and stereology by investigations blinded to the
study protocol. The following parameter were determined as
reported previously [21]: To quantify mesangial matrix accumu-
lation and sclerosis of the glomerular tuft, a score of 0 to 4 was
determined on PAS and HE stained paraffin sections (GSI =
Glomerulosclerosis index). A score of 0 was assigned for normal
glomerulus, a score of 1 indicated mesangial expansion or sclerosis
involving up to 25% of the glomerular tuft, a score of 2 indicated
sclerosis of 25 to 50%, a score of 3 described sclerosis 50 to 75%
and/or segmental extracapillary fibrosis or proliferation, and a
score of 4 indicated global sclerosis .75%, global extracapillary
fibrosis or complete collapse of the glomerular tuft.
The mesangiolysis score (MSI = Mesangiolysis index) was
determined in PAS-stained paraffin sections and graded in 100
systematically subsampled glomeruli per animal using the following
scoring system: score 0: no changes of capillaries, score 1: capillary
dilatation ,25% of the capillary convolute, score 2: capillary
dilatation .25% of the capillary convolute or capillary aneurysms
,50% of the capillary convolute, score 3: capillary aneurysms
Table 1. Primers for qRT-PCR.
ALOX5 forward 59-CGGCTTCCCTTTGAGTATTGATGC-39
reverse 59-CAGGAACTGGTAGCCAAACATGAG-39
ALOX12 forward 59-GGTTCTGCAACCTCATCACAGTTC -39
reverse 59-CCAGCAGTAGGTCTGTTGTCTTTC -39
ALOX15 forward 59-GACACTTGGTGGCTGAGGTCTTTG-39
reverse 59-GCTCCAGCTTGCTTGAGAAGATCC-39
PLA2G4A forward 59-GTTCTACGTGCCACCAAAGTAACC-39
reverse 59-TCCATGACGTAGTTGGCATCCATC-39
Cyp2c38 forward 59-CCCACTCCTTTCCCGATTAT-39
reverse 59-CAGAAAACTCCTCCCCATGA-39
probe 59-CY5-ATCAGAGCTTCCTTCACTGCTTCATACCCA-39
Cyp2c40 forward 59-AGGTCCAGCGGTACATTGAC-39
reverse 59-CACAAATCCGTTTTCCTGCT-39
probe 59-FAM-TTCATCCTCAAGGGAACACAGGTAA-39
Cyp2c44 forward 59-CAAAAAGGCTTGGTGGTGTT-39
reverse 59-CCACAGATGGCCAAATTCTC-39
probe 59-FAM-TTACATCGACTGTTTCCTCAGCAAGAT-39
EEF2 forward 59-GACATCACCAAGGGTGTGCAG-39
reverse 59-GCGGTCAGCACACTGGCATA-39
EPHX2 forward 59-GAACATGAGTCGGACTTTCAAAAGCTTCTTC-39
reverse 59-CCACAGTCCTCAATGTGTCCCCTTTTCAGG-39
doi:10.1371/journal.pone.0011979.t001
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aneurysms comprising .75% of the capillary convolute [22].
Tubulointerstitial changes, i.e. tubular atrophy, dilata-
tion, interstitial inflammation and interstitial fibrosis, and vascular
damage, i.e. wall thickening and necrosis of the vessel wall, were
assessed on HE stained paraffin sections as described at a
magnification of 1006 using a similar semi-quantitative scoring
system from 0–4 [23]. In brief, for the determination of the
tubulointerstitial damage, 10 fields per kidney were randomly
sampled and graded as follows: grade 0 – normal tubulointerstitial
structure; grade 1 – lesions involving less than 25% of the area;
grade 2 – lesions affecting 25 to 50%; grade 3 – lesions involving
more than 50% up to 75% and grade 4 with tubulointerstitial
damage in almost the entire area (TSI = Tubulointerstitial
damage index). Similarly, for the vascular damage score
interlobular and smaller arteries were graded according to the
following scheme: grade 0 – no wall thickening; grade 1, 2, 3 –
mild, moderate and severe wall thickening, respectively; grade 4 –
fibrinoid necrosis of the vascular wall.
Determination of Arachidonic acid metabolites by liquid
chromatography/tandem mass spectrometry
Blood samples were collected at the end of the experiment. After
coagulation and centrifugation, the serum was stored at 280uC.
At a later time point, samples were spiked with deuterated internal
standards (5-HETE-d8, 12-HETE-d8, 15-HETE-d8, 20-HETE-
d6, 8,9-EET-d8, 11,12-EET-d8 and 14,15-EET-d8) and extracted
twice with ethyl acetate (0.5 ml). The sEH assay was extracted
similarly but here one-tenth of organic phase was used and spiked.
After evaporation of the ethyl acetate in a vacuum block under a
gentle stream of nitrogen, the residues were reconstituted with
50 ml of methanol/water (1:1, v/v) and analyzed with a Sciex
API4000 mass spectrometer (AME Bioscience, Toroed, Norway)
operating in multiple reaction monitoring (MRM) mode as
described in detail elsewhere [24]. Chromatographic separation
was performed on a Gemini C18 column (15062 mm inner
diameter, 5 mm particle size, Phenomenex, Aschaffenburg,
Germany).
Immunoblotting
Kidney samples were mortared in liquid nitrogen. For
western blot analysis, cytosolic kidney protein (100 000 g
supernatant, 20 mg) was boiled in Laemmli buffer, separated
on sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE; 8%) and transferred onto nitrocellulose mem-
brane as described (102). Proteins were detected using
antibodies against sEH (provided by one of the coauthors) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH/Santa
Figure 1. Blood pressure and albuminuria. Blood pressure measured by tail cuff technique (A) and albuminuria (B) were determined 4 and 8
weeks after initiation of treatment. Effects of placebo, sEH-inhibition by cAUCB, ACE-inhibition by ramipril (Ramip.) and CYP-inhibition by
fenbendazole (Fenbe.) are shown on sham operated (2) and 5-6-Nx (+) animals. * p,0,05 vs. sham, # p,0,05 vs. placebo (n=10–12/group).
doi:10.1371/journal.pone.0011979.g001
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were detected using appropriate secondary antibodies labeled
with infrared dyes and visualized using the Odyssey infrared
imaging system (Li-COR Biosciences, Bad Homburg, Germany)
system. Densitometry was carried out using the integrated odys-
sey software.
Real-time quantitative reverse transcription PCR
Organs were removed, flash frozen in liquid nitrogen and
disrupted by grounding with mortar and pestle. RNA isolation was
done with Absolutely RNA Miniprep Kit (Stratagene), cDNA
synthesis with SuperScript III Reverse Transcriptase (Invitrogen)
and random hexamer primers, semiquantitative real-time PCR
with ABsolute QPCR SYBR Green Mix and ROX as reference
dye (Thermo Scientific) in Mx4000 (Stratagene) with appropriate
primers. For primer sequences please see table 1. Relative
expressions of target genes were normalized to eukaryotic
translation elongation factor 2 (EEF2), analyzed by delta-delta-
Ct method and given as percentage compared to control
experiments. PCRs for Cyp2c genes were done without SYBR
Green but with fluorescent labelled probes.
Data and statistical analysis
All values are mean 6 SEM. Statistical analysis was performed
using analysis of variance (ANOVA); ANOVA followed by
Bonferroni-corrected Fisher’s LSD test, respectively, or, wherever
appropriate, using a paired or unpaired t-test. A P value less than
0.05 was considered statistically significant.
Results
sEH inhibition does not prevent hypertension
development and augments proteinuria in the remnant
kidney model
As compared to sham operated mice, 5/6-Nx induced systemic
hypertension present 4 weeks after the operation (p,0.0.5) that
was maintained until the end of the observation period.
Surprisingly, sEH-inhibition by cis-4-[4-(3-adamantan-1-yl-ur-
eido)-cyclohexyloxy]-benzoic acid (cAUCB) had no effect on the
development of hypertension, while ACE-inhibition by Ramipril
significantly attenuated the process in 5/6-Nx mice at both time
points (Fig. 1A). Tail-cuff measurements were verified by
telemetry in a subset of animals (blood pressure in placebo treated
animals: systolic blood pressure in sham-operated mice was
11469 mmHg after 4 weeks and 11264 mmHg after 8 weeks
as compared to 169611 mmHg after 4 weeks and 16864 mmHg
after 8 weeks in 5/6-Nx; diastolic blood pressure in sham-operated
mice was 8868 mmHg after 4 weeks and 8765 mmHg after 8
weeks as compared to 12869 mmHg after 4 weeks and
12563 mmHg after 8 weeks in 5/6-Nx).
Albuminuria was determined after 4 and 8 weeks to assess renal
damage (Fig. 1B). 5/6 nephrectomy induced marked albuminuria
present at 4 weeks which was further increased 8 weeks after the
operation. As expected, ACE-inhibition significantly attenuated
the development of albuminuria. In contrast, sEH inhibition
augmented albuminuria development in 5/6-Nx mice. While this
effect was not statistically significant 4 weeks after operation,
Figure 2. Histological glomerular changes. Representative kidney sections (magnification6400) stained by periodide acid - Schiff (PAS) scoring
glomerulosclerosis index (GSI) and mesangiolysis score (MSI) after 8 weeks of treatment. Effects of placebo, sEH-inhibition by cAUCB, ACE-inhibition
by ramipril (Ramip.) and CYP-inhibition by fenbendazole (Fenbe.) are shown on sham operated (2) and 5-6-Nx (+) animals. * p,0,05 vs. sham, #
p,0,05 vs. placebo (n=5–8/group).
doi:10.1371/journal.pone.0011979.g002
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sEH inhibitor treated group as compared to placebo-treated
animals (p,0.05).
sEH inhibition does not prevent progression of renal
damage
To determine the extent of renal damage, semi-quantitative
analyses of renal damage scores were performed on histological
sections of the whole kidney. 5/6 nephrectomy lead to a significant
increase in glomerulosclerosis index (Fig. 2) and tubulo-interstitial
damage index compared to sham operated animals (Fig. 3), while
mesangiolysis index was comparable (Fig. 2 und 3). cAUCB
treatment had no effect on the development of glomerulosclerosis
and tubulo-interstitial damage compared to the placebo treated
group. In contrast, histological damage score was significantly
lower in 5/6-Nx-mice receiving ramipril (p,0.05). Accordingly,
late mortality in mice subjected to ACE inhibition but not to the
sEH inhibitor was significantly reduced as compared to placebo-
treated animals (Fig. 4).
EET plasma level are elevated in the 5/6-Nx model
In order to determine whether or not a possible shortage of
basal EET formation after 5/6-Nx underlies the failure of sEH
inhibitors to interfere with disease progression, plasma levels were
Figure 3. Histological tubulointerstitial changes. Representative kidney sections (magnification 6100) stained by Sirius Red in phase contrast
light microscopy and polarized light microscopy scoring tubulointerstitial damage index (TSI) and interstitial fibrosis after 8 weeks of treatment.
Effects of placebo, sEH-inhibition by cAUCB, ACE-inhibition by ramipril (Ramip.) and CYP-inhibition by fenbendazole (Fenbe.) are shown on sham
operated (2) and 5-6-Nx (+) animals. * p,0,05 vs. sham, # p,0,05 vs. placebo (n=5–8/group). The scale bar denotes 100 mmeter.
doi:10.1371/journal.pone.0011979.g003
sEH and Chronic Renal Failure
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e11979measured. Animals subjected to 5/6-Nx presented with signifi-
cantly increased EET plasma levels as shown for 11,12-EET
(Fig. 5). This effect was equally strong as the increase of EETs in
response to sEH inhibition by cAUCB in sham animals. Although
EET levels were already elevated in 5/6-Nx mice, sEH-inhibition
by cAUCB in 5/6-Nx- animals further increased the EET-levels
(Fig. 5). ACE-inhibitor therapy had no effect on EET plasma
levels (data not shown). Similar effects were seen for 5,6-EET, 8,9-
EET and 14,15-EET (data not shown). No significant effects were
seen on DHET plasma levels excluding product inhibition of sEH
as a possible mechanism for EET accumulation in chronic renal
failure. The latter observation suggest that renal function is not a
limiting factor for DHET excretion and my suggest that these
lipids are, potentially after conjugation in the liver, excreted via the
bile.
In order to determine whether changes in EET production
underlie the effects observed, the renal expression of sPLA2, sEH
and CYP450 enzymes was determined. Whereas the expression of
Cyp2c40 and 2c38 was unaffected by 5/6-Nx, sPLA2-mRNA
expression was increased, suggesting a possible enhanced supply of
CYP450-enzymes with arachidonic acid (Fig. 6A). Interestingly,
5/6-Nx also resulted in a marked decrease in the renal expression
of the sEH on the protein, as well as on the mRNA level (Fig. 6B).
This observation may suggest that in the diseased kidney local
effects of sEH inhibitors are less pronounced than it could be
assumed from the changes in plasma EET level. It also indicates
that the renal sEH, although highly expressed in the kidney, only
has a minor contribution to the systemic turnover of EETs.
Inhibition of sEH and 5/6-Nx results in increased plasma
level of lipoxygenase products
To further elucidate the lack of beneficial effects of sEH
inhibition on the progression of chronic renal failure, we
investigated the pro-inflammatory lipoxygenase system. 5/6-Nx
had no significant effect on the renal expression of 5-Lox and 12-
Lox, whereas a trend towards increased expression of 15-Lox was
observed. (Fig. 6C) Although this did not reach statistical
significance, 15-HETE plasma levels were the only lipoxygenase
products which were significantly higher in the plasma of mice
after 5/6-Nx receiving placebo treatment (Fig. 7). Interestingly,
this lipoxygenase product was also increased in mice receiving
sEH-inhibitor treatment and this effect was additive leading to
more than 4-fold higher plasma levels in 5/6-Nx under sEH
inhibitor treatment as compared to control animals not receiving
treatment. Also 5-HETE was increased in 5/6-Nx mice on sEH-
inhibitor treatment. In contrast, 12-HETE and the Cyp450a4-
product 20-HETE were unaffected in this scenario, excluding that
unspecific accumulation of lipid peroxides are responsible for the
effects observed. 5-HETE and 12-HETE levels were decreased
under ACE inhibitor treatment, but ACE inhibition had no effect
on 15-HETE and 20 HETE levels.
Inhibition of the CYP450 pathway in 5/6-Nx results in
accumulation of lipoxygenase products
A possible explanation for the effects on the pro-inflammatory
hydroxylipids is that high levels of EETs shift arachidonic acid into
the LOX pathways. In order to test this hypothesis, we treated a
subgroup of mice with the unspecific CYP450 inhibitor fenbenda-
zole. Fenbendazole was effective in inhibiting CYP as demon-
strated by decreased 11,12-EET (Fig. 5) and 20-HETE plasma
levels (Fig. 7). Importantly, the compound had a similar effect on
the progression of renal failure in 5/6-Nx mice as the sEH
inhibitor: It did not affect blood pressure (Fig. 1A) or histological
lesion scores (Fig. 2 and 3) but significantly increased
albuminuria after 8 weeks of treatment in 5/6-Nx mice
(Fig. 1B). Moreover, fenbendazole basically increased all
lipoxygenase products measured in this study, demonstrating that
under CYP-inhibition substantial amounts of AA are shifted into
the lipoxygenase pathway (Fig. 7).
Discussion
In this study, we determined the impact of sEH inhibition on
the progression of renal failure in mice subjected to the 5/6-Nx
model. In contrast to our expectations, sEH inhibition did not
delay disease progression but rather resulted in an increase in
albuminuria. sEH inhibition increased some lipoxygenase prod-
ucts and resulted in similar changes as observed with the broad-
spectrum CYP450 inhibitor fenbendazole. These findings may
suggest that EETs are less important in protecting the kidney than
initially anticipated but that increased formation of lipoxygenase
products by shifting of arachidonic acid from the CYP450
pathway into the LOX pathway might be important for the
progression of the disease.
Figure 4. Survival data. Kaplan-Meier survival curves after 5/6-Nx in
mice receiving the treatment indicated. n=16, Survial was significantly
better only in mice receiving ramipril.
doi:10.1371/journal.pone.0011979.g004
Figure 5. EET plasma level. 11,12-EET and 11,12-DHET plasma levels
8 weeks after initiation of treatment. Effects of placebo, sEH-inhibition
by cAUCB, and CYP-inhibition by fenbendazole (Fenbe.) are shown on
sham operated (2) and 5-6-Nx (+) animals. * p,0,05 vs. sham, #
p,0,05 vs. placebo, 1 p,0.05 vs. placebo and cAUCB (n=5–8/group).
doi:10.1371/journal.pone.0011979.g005
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hypertension. The antihypertensive effect of sEH inhibition has
been demonstrated in numerous rat and mouse models, like
spontaneously hypertensive rats, angiotensin II-induced hyperten-
sion and DOCA and salt-induced and salt-sensitive hypertension
[7,11,25,26]. The antihypertensive effect was mediated by a
decrease in vascular resistance and enhanced renal Na
+ excretion
[2,7,10,11], and all these resemble biological effects of EETs
[25,27,28].
In contrast to these observations, in the present study, sEH
inhibition had no effect on blood pressure in 5/6-Nx mice. The
pathogenesis of hypertension in chronic renal failure is however
complex: In addition to an activation of the renin angiotensin
system (RAS), sodium and water retention and thus increased
Figure 6. mRNA expression of arachidonic acid metabolizing enzymes. Relative mRNA expression (2‘-DDCT) determined by realtime RT-PCR
for the factors indicate and representative sEH Western blot (WB sEH) from the kidney of sham operated and 5/6-Nx mice at the end of the study. A:
Determination of EET-producing systems, B: qRT-PCR and Western blot for sEH. GAPDH and b-actin were used as loading control for the Western
blots. C: Expression of Lox enzymes on the RNA level. n=6, *p,0.05.
doi:10.1371/journal.pone.0011979.g006
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contribution of RAS to the hypertension thereby is not easy to
estimate. Although the ACE inhibitor ramipril prevented the
development of hypertension in the present study, it also interfered
with disease progression, making it highly probable that also
sodium and water retention were reduced by ramipril [30].
Moreover, the compound had a natriuretic effect on its own and
promotes sodium excretion by multiple ways.
It should also be mentioned that the antihypertensive effect of
sEH inhibitors is model dependent and not observed in stroke
prone SHR [31] and Goto-Kakizaki rats [32] and of a variable
degree in the different strains of SHR [31,33,34]. Also conflicting
results have been published in sEH
2/2 mice, in which the
antihypertensive effect was lost after backcrossing on the C57/BL6
background [12,30,35]. Although blood pressure lowering effects
of sEH inhibition depend on their vasodilative and natriuretic
effects, it is also possible that the renal dysfunction after 5/6-Nx
[29] attenuates the efficacy of sEH inhibition on blood pressure.
As one would expect, sEH inhibition-mediated lowering in
blood pressure exerts reno-protective effects in models of
hypertensive kidney injury [10–12]. In hypertensive models in
which sEH inhibitors failed to lower the blood pressure this reno-
protective effect was observed, too [32,35]. Also the acute renal
injury by the tubulotoxic chemotheraptic agent cisplatin was
attenuated by sEH inhibitors [36]. The latter three studies had in
common that sEH inhibition lowered several markers of
inflammation, another progression factor for renal disease.
The data of the present study demonstrated that sEH inhibition
in 5/6-Nx rather increased than decreased disease progression. In
keeping with a possible role of inflammation, we could
demonstrate that lipoxygenase products, particularly of the 15-
LOX pathway, but also of the 5-LOX pathway accumulated in 5/
6-Nx mice treated with sEH inhibitors. The biological effects of
the two LOX enzymes differ to some extent. 5-LOX is considered
pro-inflammatory in general [37] and 5-LOX inhibitors exerted
reno-protective effects [38]. 15-LOX in contrast, not only
generates pro-inflammatory lipids but 15-HETE is further
metabolized to lipoxins, which have strong anti-inflammatory
properties [39]. On the other hand, inhibition of 15-LOX had
beneficial effects on diabetic models [40] or renal injury and
mesangial cells of 12/15-LOX knockout mice had a reduced level
of activation after stimulation, which was associated with reduced
matrix production [41]. Indeed, it is important to remember that
chronic progressive renal failure is a complex disease with a strong
fibrotic contribution. Interestingly, a strong positive interplay exists
between 15-LOX-products and the pro-fibrotic transforming
growth factor b (TGF b)-pathway [42]. One limitation of all
these studies, however, is that they are predominantly performed
in glomerular cells or culture and that therefore the role of LOX
for tubulo-interstitial fibrosis has to remain unclear. Thus, also a
limitation of the present study is that we did not determine the
effect of sEH inhibition in animals lacking LOX activity and
therefore we cannot provide definite proof for an involvement of
LOX in the progression of renal failure after sEH inhibitor
treatment.
A potential explanation for the observations of the present study
is that sEH inhibition shifted arachidonic acid from the CYP450
pathway into the LOX pathway. That such shifting occurs is well
known for COX inhibitors and the basis of NSAIDS-induced
asthma [43]. Direct inhibition of CYP450 with the compound
fenbendazole [44] also increased the products of the LOX
pathway, demonstrating that shifting of arachidonic acid also
from the CYP450 pathway can occur. Given the low plasma
concentrations of EETs, it is however difficult to imagine that the
somewhat modest increase in response to sEH inhibition or renal
failure is sufficient to induce a significant product inhibition of the
CYP enzymes, although other observations supporting the
complex crosstalk have been published for inflammatory models
[45]. An alternative explanation could therefore be that the
increase in sPLA2 mRNA observed in this study results to in
overall increase in all arachidonic acid pathways. Unfortunately,
the amount of plasma samples obtained in the course of this study
did not allow us to analyze the lipidom in more detail to further
clarify this point. We therefore also did not measure the different
enantiomers of the HETEs to definitely prove that the increase of
this hydroxylipids is a consequence of the action of LOX and not
of lipid peroxidation.
In this study we observed that the sEH expression decreases
during progressive renal failure. As this effect occurred on the
message as well as on the protein level, it is unlikely that changes in
the matrix composition which occur during the fibrotic remod-
eling of the kidney could account for this observation. Interest-
Figure 7. Plasma levels of hydroxyeicosatetraenoic (HETE)
acids. Plasma level of 5-HETE, 12-HETE, 15-HETE and 20-HETE as
determined by LC-MS/MS 8 weeks after initiation of treatment. Effects
of placebo, sEH-inhibition by cAUCB, ACE-inhibition by ramipril (Ramip.)
and CYP-inhibition by fenbendazole (Fenbe.) are shown on sham
operated (2) and 5-6-Nx (+) animals. * p,0,05 vs. sham, # p,0,05 vs.
placebo, 1 p,0.05 vs. placebo all groups (n=5–8/group).
doi:10.1371/journal.pone.0011979.g007
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occurring during pulmonary hypertension reduced the sEH
expression [9] suggesting that this effect is more important than
the previously reported induction of sEH by angiotensin II [46].
The fact that the relative increase in plasma EET level were
similar between normal mice and those in renal failure suggest that
the renal sEH contributes little to the EET plasma level. The
increase in EET plasma level in response to 5/6-Nx is either a
consequence of a reduced renal excretion or of a greater formation
of EET under this condition.
Independently of the mechanism of increased EET plasma
level, the present study demonstrates that lowering sEH activity is
not necessarily beneficial. Importantly, this notion is also
supported by data on human polymorphisms: In kidney
transplanted patients a gene polymorphism leading to reduced
sEH activity was linked to allograft dysfunction and decreased
graft survival [47].
In conclusion, in the present study we demonstrate that sEH
inhibition rather promotes than delays the progression of chronic
renal failure in mice. As a possible mechanism we suggest the
accumulation of inflammatory lipoxygenase products. Thus,
chronic renal failure as a possible drug target for sEH inhibitors
should be reconsidered.
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